Responses
Clinical and epidemiological research
Extended report
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
Compose a Response to This Article
Other responses
No responses have been published for this article.